202P - Reactive oxygen species modulator 1 (Romo1) as a prognostic biomarker for colorectal cancer patients who have curative resection

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Colon and Rectal Cancer
Rectal Cancer
Translational Research
Presenter Hong Jun Kim
Citation Annals of Oncology (2016) 27 (suppl_9): ix53-ix67. 10.1093/annonc/mdw581
Authors H.J. Kim, S.C. Oh
  • Division Of Oncology/hematology, Department Of Internal Medicine, Korea University Medical Center, 08308 - Seoul/KR

Abstract

Background

Reactive oxygen species modulator 1 (Romo1) is a novel protein that plays a crucial role in intracellular reactive oxygen species regulation. In most cancer cell lines, Romo1 is highly expressed and associated with invasiveness and tumor development in vitro. However, its clinical implications in colorectal cancer (CRC) patients are not known well. For the first time, we investigated the association between Romo1 expression and the clinical outcomes of CRC patients who underwent curatively surgical resection.

Methods

Romo1 protein expressions in surgically resected tumor tissues were examined immunohistochemically and assessed by histological score. Survival analyses for overall population (n = 208) were performed according to clinical parameters including level of Romo1 expression. The association between Romo1 level and cell invasion was examined using matrigel invasion assay in CRC cell lines.

Results

Significantly longer median disease free survival (DFS) was observed in the low Romo1 group compared with the high Romo1 group (160.1 vs 125.1 months, p = 0.012), and the median overall survival (OS) of the low Romo1 group was significantly longer than that of the high Romo1 group (195.4 vs 162.4 months, p = 0.003). Multivariate analyses showed that high Romo1 expression in tumor tissues was significantly associated with short DFS (hazard ratio [HR]=2.14, 95% confidence interval [CI]: 1.21∼3.78), and with short OS (HR = 3.13, 95% CI:1.37∼7.19). Cell invasion was decreased in Romo1 siRNA transfected CRC cell line in contrast to controlled cell line. Romo1 overexpression in tumor tissue was associated with high lymph node ratio (LNR) between metastatic and examined lymph nodes (p = 0.025).

Conclusions

Romo1 overexpression in tumor tissue was significantly associated with poor clinical outcomes in curatively resected CRC patients. Increased Romo1 expression could be a potential adverse prognostic marker. Increased Romo1 level is found to be associated with high LNR.

Clinical trial indentification

Legal entity responsible for the study

Korea University Medical Center

Funding

Korea University Medical Center

Disclosure

All authors have declared no conflicts of interest.